<DOC>
	<DOC>NCT00362323</DOC>
	<brief_summary>To demonstrate in patients with T2DM and dyslipidemia not appropriately controlled with a statin and receiving metformin, the superiority of a fixed combination of fenofibrate and metformin vs metformin alone on TG and additionally, if the superiority on TG is established, to demonstrate the superiority on HDL-C</brief_summary>
	<brief_title>Fenofibrate and Metformin Fixed Combination vs Metformin - FAME METFO</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Glucose Metabolism Disorders</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Inclusion Criteria Patient with Type 2 Diabetes treated with stable dose of metformin and with dyslipidemia not appropriately controlled with a statin treatment. Exclusion Criteria Type 1 diabetes.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Treatment of Dyslipidemia and of Type 2 Diabetes Mellitus</keyword>
</DOC>